株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

免疫チェックポイント阻害剤市場: 市場機会分析および将来予測

Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

発行 Coherent Market Insights 商品コード 817599
出版日 ページ情報 英文 238 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.53円で換算しております。
Back to Top
免疫チェックポイント阻害剤市場: 市場機会分析および将来予測 Immune Checkpoint Inhibitors Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
出版日: 2019年03月25日 ページ情報: 英文 238 Pages
概要

当レポートでは、免疫チェックポイント阻害剤の世界市場を調査し、市場の概要、タイプ、用途、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:薬剤クラス別
    • 市場スニペット:用途別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場のダイナミクス、規制、動向分析

  • マーケットダイナミクス
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 疫学
  • 提携とパートナーシップ
  • 主なFDAの承認と製品発売のシナリオ
  • パイプライン分析
  • 規制シナリオ
  • 還付シナリオ
  • PEST分析
  • ファイブフォース分析

第4章 免疫チェックポイント阻害剤市場:薬剤クラス別

  • イントロダクション
  • PD-1 阻害剤
  • PD-L1 阻害剤
  • CTL-4 阻害剤
  • IDO 阻害剤
  • リンパ球活性化遺伝子3 阻害剤

第5章 免疫チェックポイント阻害剤市場:用途別

  • イントロダクション
  • 肺がん
  • 頭頸部がん
  • 皮膚がん(メラノーマ・メルケル細胞がん)
  • 血液がん(リンパ腫)
  • 膀胱がん(尿路上皮がん)
  • 腎臓/腎臓がん
  • 大腸がん
  • 乳がん
  • その他

第6章 免疫チェックポイント阻害剤市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 免疫チェックポイント阻害剤市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • 中南米
  • 中東
  • アフリカ

第8章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.

第9章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Immune checkpoint inhibitor products come under biologic therapeutic products. Biologic manufacturers require similar kind of approvals such as drugs from the U.S. Food & Drug Administration prior to bringing the product into market. However, unlike drugs, biologics require Biologics License Applications (BLA) to be filed with the Center for Biologics Evaluation and Research (CBER). Initiatives undertaken by the governments include funding is expected to drive growth of the immune checkpoint inhibitors market. For instance, in 2017, National Institutes of Health partnered with 11 leading biopharmaceutical companies such as AbbVie and Amgen, Inc. to accelerate development of new immunotherapies.

Market Dynamics

Global Immune checkpoint inhibitors market is driven by factors such as increasing prevalence of cancer, active research and development by leading manufacturers through collaborations and individual research, and robust pipeline of immune checkpoint inhibitor combination therapies. According to World Health Organization (WHO), cancer is one of the major non-communicable diseases and the second-leading cause of death worldwide. According to International Agency for Research on Cancer (IARC) in 2012, there were around 14.1 million new cases, around 8.8 million deaths, and around 32.6 million of people suffering from cancer worldwide. There are many immune checkpoint inhibitors combination therapies in the pipeline. Immune checkpoint inhibitors has proven clinical profile and increasing approvals to include more indication for existing drugs such as Nivolumab, which in turn is expected to boost global immune checkpoint inhibitors market growth over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of Global Immune Checkpoint Inhibitors Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018-2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the Global Immune Checkpoint Inhibitors Market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Novartis International AG, ImmunOs Therapeutics AG, Immutep Ltd., NewLink Genetics Corporation, Ono Pharmaceutical Co., Ltd., and Pfizer, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, By Technology up-gradation, market expansion, and marketing tactics
  • The global immune checkpoint inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Global Immune Checkpoint Inhibitors Market

Detailed Segmentation:

  • Global Immune Checkpoint Inhibitors Market, By Drug Class:
    • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
    • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
    • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
    • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
    • Lymphocyte-Activation Gene 3 Inhibitors
  • Global Immune Checkpoint Inhibitors Market, By Cancer Type:
    • Lung Cancer
    • Head & Neck Cancer
    • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Blood Cancer (Lymphoma)
    • Bladder Cancer (Urothelial Carcinoma)
    • Renal/Kidney Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Others
  • Global Immune Checkpoint Inhibitors Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immune Checkpoint Inhibitors Market, By Geography:
    • North America
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Russia
      • Spain
      • Rest of Europe
    • Asia Pacific
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of APAC
    • Latin America
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of LATAM
    • Middle East
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class
      • Programmed Death Receptor-1 (PD-1) Inhibitors
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Cemiplimab (Libtayo)
      • Others
      • Programmed Death-Ligand 1 (PD-L1) Inhibitors
      • Atezolizumab (Tecentriq)
      • Avelumab (Bavencio)
      • Durvalumab (Imfinzi)
      • CTL-4 Checkpoint Inhibitor
      • Ipilimumab (Yervoy)
      • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
      • Lymphocyte-Activation Gene 3 Inhibitors
      • By Cancer Type:
      • Lung Cancer
      • Head & Neck Cancer
      • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
      • Blood Cancer (Lymphoma)
      • Bladder Cancer (Urothelial Carcinoma)
      • Renal/Kidney Cancer
      • Colorectal Cancer
      • Breast Cancer
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • North Africa
      • Central Africa
      • South Africa
  • Company Profiles
    • Bristol-Myers Squibb Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • AstraZeneca Plc
    • Novartis International AG
    • ImmunOs Therapeutics AG
    • Immutep Ltd.
    • NewLink Genetics Corporation
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Collaborations & Partnerships
  • Major FDA Approvals & Product Launch Scenario
  • Pipeline Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Porter's Five Forces Analysis

4. Global Immune Checkpoint Inhibitors Market, By Drug Class, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Programmed Death Receptor-1 (PD-1) Inhibitors
    • Pembrolizumab (Keytruda)
    • Nivolumab (Opdivo)
    • Cemiplimab (Libtayo)
    • Others
  • Programmed Death-Ligand 1 (PD-L1) Inhibitors
    • Atezolizumab (Tecentriq)
    • Avelumab (Bavencio)
    • Durvalumab (Imfinzi)
  • CTL-4 Checkpoint Inhibitor
    • Ipilimumab (Yervoy)
  • Indoleamine-2,3-dioxygenase (IDO) Inhibitors
  • Lymphocyte-Activation Gene 3 Inhibitors

5. Global Immune Checkpoint Inhibitors Market, By Application, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Head & Neck Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Skin Cancer (Melanoma and Merkel Cell Carcinoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Blood Cancer (Lymphoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Bladder Cancer (Urothelial Carcinoma)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Renal/Kidney Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

6. Global Immune Checkpoint Inhibitors Market, By Distribution Channel, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

7. Global Immune Checkpoint Inhibitors Market, By Regions, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
  • North America
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AstraZeneca Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • ImmunOs Therapeutics AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Immutep Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • NewLink Genetics Corporation
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Ono Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top